| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
48,410,000 |
| Market
Cap: |
1.60(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.78 - $35.53 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
122,882 |
757,560 |
| Total Buy Value |
$0 |
$0 |
$1,407,368 |
$3,550,945 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
5 |
14 |
| Total Shares Sold |
27,000 |
27,000 |
27,000 |
27,000 |
| Total Sell Value |
$807,792 |
$807,792 |
$807,792 |
$807,792 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
3 |
3 |
3 |
3 |
| End Date |
2025-11-09 |
2025-08-08 |
2025-02-07 |
2024-02-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sandler Laura Lee |
Chief Operating Officer |
• – – |
2026-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
32,500 |
237,584 |
|
- |
|
| Goncalves Joana |
Chief Medical Officer |
• – – |
2026-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
32,500 |
34,018 |
|
- |
|
| Klein Lawrence Otto |
Chief Executive Officer |
• • – |
2026-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
76,700 |
929,038 |
|
- |
|
| Agarwal Arjun |
SVP, Finance |
• – – |
2026-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
19,258 |
|
- |
|
| Quinlan Paul T |
General Counsel |
• – – |
2026-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
32,500 |
32,500 |
|
- |
|
| Dambkowski Carl |
Director |
– • – |
2026-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
116,483 |
116,483 |
|
- |
|
| Goncalves Joana |
Chief Medical Officer |
• – – |
2026-01-15 |
4 |
AS |
$31.56 |
$222,704 |
D/D |
(7,000) |
1,518 |
|
5% |
|
| Goncalves Joana |
Chief Medical Officer |
• – – |
2026-01-15 |
4 |
OE |
$6.84 |
$51,240 |
D/D |
7,000 |
8,518 |
|
- |
|
| Sandler Laura Lee |
Chief Operating Officer |
• – – |
2026-01-02 |
4 |
AS |
$28.17 |
$370,795 |
D/D |
(13,000) |
205,084 |
|
21% |
|
| Sandler Laura Lee |
Chief Operating Officer |
• – – |
2026-01-02 |
4 |
OE |
$7.80 |
$39,000 |
D/D |
5,000 |
218,084 |
|
- |
|
| Goncalves Joana |
Chief Medical Officer |
• – – |
2025-12-19 |
4 |
AS |
$28.53 |
$214,293 |
D/D |
(7,000) |
1,518 |
|
8% |
|
| Goncalves Joana |
Chief Medical Officer |
• – – |
2025-12-19 |
4 |
OE |
$6.84 |
$51,240 |
D/D |
7,000 |
8,518 |
|
- |
|
| Harwin Peter Evan |
Director |
– • • |
2025-09-17 |
4 |
A |
$15.00 |
$5,000,100 |
I/I |
333,340 |
1,131,954 |
|
- |
|
| Sandler Laura Lee |
Chief Operating OfficerOfficer |
• – – |
2025-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
213,084 |
|
140% |
|
| Shah Nimish P |
10% Owner |
– – • |
2025-02-14 |
4 |
B |
$11.44 |
$1,015,803 |
I/I |
88,794 |
4,148,428 |
1.5 |
4% |
|
| Shah Nimish P |
10% Owner |
– – • |
2025-02-13 |
4 |
B |
$11.63 |
$173,869 |
I/I |
14,950 |
4,059,634 |
1.5 |
2% |
|
| Shah Nimish P |
10% Owner |
– – • |
2025-02-12 |
4 |
B |
$11.86 |
$106,396 |
I/I |
8,971 |
4,044,684 |
1.5 |
-1% |
|
| Shah Nimish P |
10% Owner |
– – • |
2025-02-11 |
4 |
B |
$10.95 |
$105,043 |
I/I |
9,593 |
4,035,713 |
1.5 |
-1% |
|
| Shah Nimish P |
10% Owner |
– – • |
2025-02-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,025,546 |
|
7% |
|
| Shah Nimish P |
10% Owner |
– – • |
2025-02-10 |
4 |
B |
$10.90 |
$6,257 |
I/I |
574 |
4,026,120 |
1.5 |
7% |
|
| Harwin Peter Evan |
Director |
– • • |
2024-11-19 |
4 |
OE |
$0.00 |
$0 |
I/I |
160,000 |
798,614 |
|
- |
|
| Harwin Peter Evan |
Director |
– • • |
2024-09-11 |
4 |
A |
$23.00 |
$6,325,000 |
I/I |
275,000 |
638,614 |
|
- |
|
| Klein Lawrence Otto |
President and CEOOfficer |
• • – |
2024-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
852,338 |
|
- |
|
| Turtle Cameron |
Director |
– • – |
2024-08-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
85,233 |
|
- |
|
| Harwin Peter Evan |
Director |
– • • |
2024-08-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,936,922 |
|
- |
|
116 Records found
|
|
Page 1 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
1.63 (5.19%) 
